AstraZeneca PLC (AZN)'s Antibiotics Alums Emerge at Biotech Spinout Entasis Therapeutics
Baxter International (BAX) Spinout Baxalta Finally Has Long Awaited Launch
Feds Want Novartis AG (NVS) to Fork Over $3.35 Billion for Kickback Schemes
GlaxoSmithKline (GSK) Discloses $175K Paid to Hundreds of North Carolina Doctors
Seattle’s Adaptive Biotech Will Set Up Shop in New York
GlaxoSmithKline (GSK) Will Receive $140B+ Bid in Q4, From Suitors Including Pfizer (PFE) and AstraZeneca PLC (AZN): Poll
Evotec AG (EVTG.F), Roche (RHHBY)'s Alzheimer's Hopeful Fails Another Trial
Sarepta (SRPT) Bags Ex-Genzyme (GENZ) CEO as Advisor to the Company
EXCLUSIVE: Gene Therapy M&A Booms, Increasing 40-Fold to $4.9 Billion
EXCLUSIVE: Juno Therapeutics (JUNO)/Celgene (CELG) Deal "Great Validation" for Cellular Therapy, TxCell CEO Tells BioSpace (DHX)
Genentech (RHHBY)'s Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market
Juno Therapeutics (JUNO) Stock Soars After Celgene (CELG) Acquires $1 Billion Stake in Seattle Company
Vertex (VRTX) Poised to Become Profitable Following Expected FDA Approval of Orkambi
New Sarepta (SRPT) CEO's Strategy Bears Fruit With NDA Filing
Amgen (AMGN) To Lay Off 330 in Colorado as Part of Almost 4,000 Jobs Cuts Overall
Roche (RHHBY) Investors Urging Company to Dump Diabetes Unit May Have to Wait
Two Yale University Health Info Groups Sue FDA, Gilead (GILD) for Hep C Drug Trial Data
EXCLUSIVE: Analysts Weigh In On Controversial Juno Therapeutics (JUNO)/Celgene (CELG) Deal, With Mixed Feelings Abounding
See All News >
Genentech (RHHBY)'s Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market
Juno Therapeutics (JUNO) Stock Soars After Celgene (CELG) Acquires $1 Billion Stake in Seattle Company
Vertex (VRTX) Poised to Become Profitable Following Expected FDA Approval of Orkambi
New Sarepta (SRPT) CEO's Strategy Bears Fruit With NDA Filing
Amgen (AMGN) To Lay Off 330 in Colorado as Part of Almost 4,000 Jobs Cuts Overall
Roche (RHHBY) Investors Urging Company to Dump Diabetes Unit May Have to Wait
Two Yale University Health Info Groups Sue FDA, Gilead (GILD) for Hep C Drug Trial Data
EXCLUSIVE: Analysts Weigh In On Controversial Juno Therapeutics (JUNO)/Celgene (CELG) Deal, With Mixed Feelings Abounding
Hikma (HIK.L) Rumored to Be Bidding $2.2B for Boehringer Ingelheim's Roxane Laboratories, As Mallinckrodt (MNK), Perrigo (PRGO) Circle
Bristol-Myers Squibb (BMY) to Lay Off 100 in Discovery, Move 200 Workers to New Cambridge R&D Hub
AMAG (AMAG) Coughs Up $700 Million for Stem Cell Company
You Can Freeze Your Fat And Poop It Out
Merck & Co. (MRK) Slashes Contractor Positions at Durham Vaccine Manufacturing Plant
GlaxoSmithKline (GSK)'s Major Gene Discovery Paves Way for "Home Brew" Heroine
BioSpace (DHX) Temperature Poll: After Bristol-Myers Squibb (BMY) Wonder Drug Meets Endpoints, Will FDA Process Be Up to Snuff?
Billionaire Doctor's NantHealth Inches Closer to an IPO
EXCLUSIVE: Knives Are Out for Biotech, As Bears Snag Options for Bubble Burst
Vitae Pharma (VTAE)’ Diabetes Drug Fails Mid-Stage Trial, the Second Drug in Less Than Six Months to Fail
See All News >
//-->